samedan logo
 
 
 
spacer
home > ebr > spring 2017 > managing e&l unknown compounds
PUBLICATIONS
European Biopharmaceutical Review

Managing E&L Unknown Compounds

Unknown compound characterisation has always been one of the most challenging aspects of analytical chemistry. Despite the difficulties, this identification is critical for a meaningful extractables and leachables (E&L) evaluation of container closure systems; single-use systems; drug delivery and combination products; and medical devices.

Identification of unknown extractable compounds is key to a successful E&L study due to the fact that there is no universally established concentration limit for leachable compounds. As a result, a toxicological risk assessment based on the intended dosing regimen of the product is required to determine if a potential leachable compound poses a risk to patient safety. Unfortunately, accurate and meaningful toxicological assessments are not possible for unknown compounds. These are typically assessed using a worst case scenario, where they are evaluated as extremely toxic – this however often leads to applying an inaccurate level of risk. Therefore, a systematic approach for the characterisation of unknown extractable compounds is essential to enable scientists to assign the correct degree of toxicological concern to a given analyte.

So, how does one go about identifying an unknown compound? The use of the proper instrumentation is critical. High resolution mass spectrometers that enable an accurate mass determination to at least three decimal places – such as liquid chromatographyquadrupole time of flights (LC-QTOFs) and gas chromatography (GC)-QTOFs – are suitable for this purpose and their use generates a plethora of data that can often lead to the identification of an empirical formula or class of compound for the unknown. This information can then be further evaluated with specialised software that is able to quickly search historical data and databases to provide a preliminary identification of the unknown extractable compound.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Simone Carrara, E&L Laboratory Manager; Andrew Blakinger, Manager, Extractables & Leachables Testing; Thomas Lehman, PhD, Director, Method Development and Validation and Extractables and Leachables, Eurofins BioPharma Product Testing
spacer
Simone Carrara
spacer
spacer
spacer
Andrew Blakinger
spacer
spacer
spacer
Thomas Lehman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Moderna Announces FDA Advisory Committee Unanimously Votes in Support of Emergency Use for a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that the FDA grant an Emergency Use Authorization (EUA) for a booster dose of the Moderna COVID-19 vaccine.
More info >>

White Papers

Translating Cancer Genomics Into A Personalised Approach For Cancer Patients

PRA Health Sciences (PRA)

Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement